Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
EXCLI J ; 20: 948-955, 2021.
Article in English | MEDLINE | ID: mdl-34177410

ABSTRACT

The aim of this case series is to clarify if a physiotherapy program can reduce the frequency, intensity and duration of the headache episodes in patients with cluster headache. A 7-case series with cluster headache patients was conducted. Every subject received physiotherapy treatment based on manual therapy and exercise, maintaining pharmacological treatment prescribed by the neurologist. Frequency, intensity and duration of the episodes, pressure pain thresholds (PPT) and psychological variables were measured 5 times: pre-intervention, post-intervention, 1 month follow-up, 2 months follow-up and 3 months follow-up. Two of the seven subjects decreased their frequency of headaches over 50 % and another in 16,67 %. There were no significant changes in duration or intensity. Results also showed an improvement in impact of headache in 6 of 7 cases. Those cases that decreased more their headache frequency also decreased their pain catastrophizing. A program of physiotherapy based in manual therapy and exercise, might be an effective and safe complement to decrease the frequency of the episodes of CH in short-term (4 months follow-up) including interdisciplinary working with neurologists and other health care professionals.

2.
Pain Med ; 20(12): 2562-2570, 2019 12 01.
Article in English | MEDLINE | ID: mdl-30958885

ABSTRACT

OBJECTIVE: To investigate central sensitization (CS) in cluster headache (CH) and to evaluate its relationship with disease characteristics and psychological comorbidities. DESIGN: Cross-sectional study. SETTINGS: Whether CS occurs in CH, as it does in other primary headaches, is a subject of debate. Few studies have evaluated the presence of CS and its relationship with psychological comorbidities in patients with CH. SUBJECTS: Twenty patients with episodic or chronic CH and 16 healthy controls were recruited. METHODS: The variables evaluated included frequency, intensity and duration of headache attacks, pressure pain thresholds (PPTs) and wind-up (WU) ratios of pain bilaterally measured over trigeminal and extratrigeminal areas, and results of questionnaires regarding anxiety and depression (Hospital Anxiety and Depression Scale [HADS], Beck Depression Inventory [BDI], State-Trait Anxiety Inventory [STAI]), quality of life (Short Form-36 [SF-36]), headache impact (Headache Impact Test [HIT-6]), and allodynia (Allodynia Symptom Checklist [ASC]). RESULTS: PPT levels were significantly lower in the CH group compared with the healthy participants (all tested points, P < 0.001). No differences were found in WU ratios between groups. However, differences in HADS (P < 0.01), BDI (P < 0.01), STAI (P < 0.01), SF-36 (P < 0.01), HIT-6 (P < 0.001), and ASC (P < 0.01) were observed between groups. The healthy group showed a moderate negative correlation between SF-36 and BDI (rho = -0.59, P = 0.03). Likewise, the CH group showed a moderate negative correlation between frequency and BDI (rho = -0.52, P = 0.03), a strong positive correlation between duration and HADS (rho = 0.86, P < 0.01), and a moderate negative correlation between intensity and PPT over symptomatic V1 (rho = -0.66, P < 0.01) and over asymptomatic V1 (rho = -0.65, P < 0.01). The CH group also showed a moderate negative correlation between SF-36 and anxiety and depression variables. CONCLUSIONS: Our findings show that patients with CH have lower PPT levels at cranial and extracranial points, suggesting, as in other primary headaches, the presence of CS. We have also found a high prevalence of psychiatric comorbidities that correlate with the length and frequency of attacks. These findings highlight the importance of a multidisciplinary approach to the treatment of patients with CH.


Subject(s)
Central Nervous System Sensitization , Cluster Headache/epidemiology , Hyperalgesia/epidemiology , Adult , Aged , Anxiety/epidemiology , Anxiety/psychology , Case-Control Studies , Cluster Headache/physiopathology , Cluster Headache/psychology , Cross-Sectional Studies , Depression/epidemiology , Depression/psychology , Female , Humans , Hyperalgesia/psychology , Male , Middle Aged , Pain Threshold , Quality of Life , Young Adult
3.
Pain Med ; 18(11): 2214-2223, 2017 Nov 01.
Article in English | MEDLINE | ID: mdl-28575454

ABSTRACT

OBJECTIVE: To compare patients with chronic migraine (CM) and chronic temporomandibular disorders (TMD) on disability, pain, and fear avoidance factors and to associate these variables within groups. DESIGN: Descriptive, cross-sectional study. SETTINGS: A neurology department and a temporomandibular disorders consult in a tertiary care center. SUBJECTS: A total of 50 patients with CM and 51 patients with chronic TMD, classified by international criteria classifications. METHODS: The variables evaluated included pain intensity (visual analog scale [VAS]), neck disability (NDI), craniofacial pain and disability (CF-PDI), headache impact (HIT-6), pain catastrophizing (PCS), and kinesiophobia (TSK-11). RESULTS: Statistically significant differences were found between the CM group and the chronic TMD group in CF-PDI (P < 0.001), PCS (P = 0.03), and HIT-6 (P < 0.001); however, there were no differences between the CM group and the VAS, NDI, and TSK-11 groups (P > 0.05). For the chronic TMD group, the combination of NDI and TSK-11 was a significant covariate model of CF-PDI (adjusted R2 = 0.34). In the CM group, the regression model showed that NDI was a significant predictive factor for HIT-6 (adjusted R2 = 0.19). CONCLUSIONS: Differences between the CM group and the chronic TMD group were found in craniofacial pain and disability, pain catastrophizing, and headache impact, but they were similar for pain intensity, neck disability, and kinesiophobia. Neck disability and kinesiophobia were covariates of craniofacial pain and disability (34% of variance) for chronic TMD. In the CM group, neck disability was a predictive factor for headache impact (19.3% of variance).


Subject(s)
Avoidance Learning/physiology , Facial Pain/drug therapy , Pain Measurement , Temporomandibular Joint Disorders/drug therapy , Adolescent , Adult , Cross-Sectional Studies , Disability Evaluation , Facial Pain/physiopathology , Fear/physiology , Female , Headache/drug therapy , Headache/physiopathology , Humans , Male , Migraine Disorders/drug therapy , Migraine Disorders/physiopathology , Young Adult
4.
J Immunol ; 198(5): 2038-2046, 2017 03 01.
Article in English | MEDLINE | ID: mdl-28115526

ABSTRACT

Patients with acute ischemic stroke (AIS) suffer from infections associated with mortality. The relevance of the innate immune system, and monocytes in particular, has emerged as an important factor in the evolution of these infections. The study enrolled 14 patients with AIS, without previous treatment, and 10 healthy controls. In the present study, we show that monocytes from patients with AIS exhibit a refractory state or endotoxin tolerance. The patients were unable to orchestrate an inflammatory response against LPS and expressed three factors reported to control the evolution of human monocytes into a refractory state: IL-1R-associated kinase-M, NFkB2/p100, and hypoxia-inducible factor-1α. The levels of circulating mitochondrial DNA (mtDNA) in patients with AIS correlated with impaired inflammatory response of isolated monocytes. Interestingly, the patients could be classified into two groups: those who were infected and those who were not, according to circulating mtDNA levels. This finding was validated in an independent cohort of 23 patients with AIS. Additionally, monocytes from healthy controls, cultured in the presence of both sera from patients and mtDNA, reproduced a refractory state after endotoxin challenge. This effect was negated by either a TLR9 antagonist or DNase treatment. The present data further extend our understanding of endotoxin tolerance implications in AIS. A putative role of mtDNA as a new biomarker of stroke-associated infections, and thus a clinical target for preventing poststroke infection, has also been identified.


Subject(s)
Biomarkers/blood , Blood Cells/immunology , DNA, Mitochondrial/blood , Infections/immunology , Ischemia/immunology , Monocytes/immunology , Stroke/immunology , Acute Disease , Aged , Aged, 80 and over , Cells, Cultured , Endotoxins/immunology , Female , Humans , Immune Tolerance , Immunity, Innate , Infections/etiology , Ischemia/complications , Male , Middle Aged , Stroke/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...